Accelerate Diagnostics, Inc. announced that it has entered into a securities purchase agreement to issue 33,332 units at a price of $1.5 per unit for the gross proceeds of $49,998 and 2,716,763 units at a price of $1.73 per unit for the gross proceeds of $4,699,999.99 for the total gross proceeds of $4,749,996 on January 19, 2024. The transaction will include participation from individual investors, Chief Executive Officer and Chief Financial Officer for $49,998 and returning investor, Jack W. Schuler Living Trust for $4,749,996. The transaction became effective as of May 20, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.16 USD | -9.38% |
|
-8.66% | -70.41% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-70.41% | 27.39M | |
+7.23% | 217B | |
+11.31% | 191B | |
+28.94% | 154B | |
+32.00% | 112B | |
-0.30% | 62.75B | |
+16.09% | 53.34B | |
+0.94% | 48.88B | |
-2.97% | 39.36B | |
+1.23% | 35.73B |
- Stock Market
- Equities
- AXDX Stock
- News Accelerate Diagnostics, Inc.
- Accelerate Diagnostics, Inc. announced that it expects to receive $4.749998 million in funding from Jack W. Schuler Living Trust